Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Caris Life Sciences, Inc.

Market Cap 4.85B 0 0 0 0 0 0 46.29B 17.92B 224B 18.21B 0 0 P/E Ratio 2026 *
169x
P/E Ratio 2027 * 53x
Enterprise Value 4.42B 0 0 0 0 0 0 42.17B 16.33B 204B 16.59B 0 0 EV / Sales 2026 *
4.4x
EV / Sales 2027 * 3.5x
Free-Float
51.2%
Yield 2026 *
-
Yield 2027 * -
Jun. 08 Caris Life Sciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 10:40 AM
Jun. 08 Caris Life Sciences, Inc. authorizes a Buyback plan. CI
Jun. 08 Caris Life Sciences, Inc. announces an Equity Buyback for $100 million worth of its shares. CI
May. 22 Caris Life Sciences Presents 32 Studies At Asco 2026 Highlighting Advances in Multi-Omic Biomarker Research and Real-World Evidence CI
May. 15 Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris Mi Cancer Seek CI
May. 12 Caris Life Sciences, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10:00 AM
May. 12 Caris Life Sciences Insider Bought Shares Worth $501,426, According to a Recent SEC Filing MT
May. 11 Caris Life Sciences Publishes Study Showing Whole Exome Measurement Of Tumor Mutational Burden Results In Increased Overall Survival Compared To Estimates From Targeted Gene Panels CI
May. 08 Caris Life Sciences Submits Application for Molecular Profiling Test in New York State MT
May. 08 Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood-Based Testing Authorization CI
May. 07 Caris Life Sciences, Inc., Q1 2026 Earnings Call, May 07, 2026
May. 07 Caris Life Sciences Reports Q1 Breakeven Results, Revenue Rises; 2026 Guidance Reaffirmed MT
May. 07 Earnings Flash (CAI) Caris Life Sciences Posts Q1 EPS $0.0, vs. FactSet Est of -$0.02 MT
1 day+2.33%
1 week+1.48%
Current month+4.87%
1 month+10.01%
3 months-5.83%
6 months-33.93%
Current year-35.01%
1 week 15.78
Extreme 15.7807
17.8
1 month 14.19
Extreme 14.19
17.84
Current year 14.19
Extreme 14.19
29.32
1 year 14.19
Extreme 14.19
42.5
3 years 14.19
Extreme 14.19
42.5
5 years 14.19
Extreme 14.19
42.5
10 years 14.19
Extreme 14.19
42.5
Manager TitleAgeSince
Chief Executive Officer 70 2007-12-31
Director of Finance/CFO 45 2023-01-31
President 50 2016-10-31
Director TitleAgeSince
Chairman 70 2007-12-31
Director/Board Member 60 2007-12-31
Director/Board Member 78 2009-12-31
Date Insider Type Main position Quantity % Market Cap.
May. 28Free

Director

1,600 0.0006%
May. 28Free

Director

1,600 0.0006%
May. 14Tax

Chief Executive Officer

-40,712 0.0145%
Change 5-day change 1-year change 3-year change Capi.($)
+2.24%+1.48% - - 4.85B
+1.54%-1.29%+167.88%+278.17% 17.33B
-1.71%-6.06%-43.53%-24.20% 9.56B
+2.09%-0.36%+26.87%+21.99% 6.53B
+3.35%-1.69%-31.63%-24.44% 4.91B
-2.25%-4.99%-27.57%-29.66% 4.29B
-4.99%-20.03%+64.03%+50.59% 4.01B
-0.29%-13.07%+170.13%-47.86% 3.7B
+2.20%+0.16%-20.38%-42.78% 2.56B
+0.31%-0.88%-35.35%-57.28% 1.37B
Average +0.32%-0.54%+30.05%+13.84% 5.91B
Weighted average by Cap. +0.47%+0.33%+58.61%+79.69%

Financials

2026 *2027 *
Net sales 1B 0 0 0 0 0 0 9.58B 3.71B 46.35B 3.77B 0 0 1.2B 0 0 0 0 0 0 11.49B 4.45B 55.58B 4.52B 0 0
Net income 28.98M 0 0 0 0 0 0 277M 107M 1.34B 109M 0 0 97.94M 0 0 0 0 0 0 935M 362M 4.52B 368M 0 0
Net Debt -431M -0 -0 -0 -0 -0 -0 -4.12B -1.59B -19.91B -1.62B -0 -0 -636M -0 -0 -0 -0 -0 -0 -6.07B -2.35B -29.36B -2.39B -0 -0
Logo Caris Life Sciences, Inc.
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Employees
1,846
Date Price Change Volume
26-06-11 17.55 $ +2.27% 772,043
26-06-10 17.16 $ +1.18% 2,606,038
26-06-09 16.96 $ +5.08% 3,534,150
26-06-08 16.14 $ -2.12% 3,402,995
26-06-05 16.49 $ -4.57% 2,740,812
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
17.16USD
Average target price
27.83USD
Spread / Average Target
+62.20%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!